ITGAM and relapsing-remitting multiple sclerosis: The high levels of NOX activation in peripheral CD11b+ cells of mice with EAE and of untreated RRMS patients could be ameliorated by treatment with glatiramer acetate (GA) alone, to only 10.8 ± 2.8 % (in RRMS patients).